ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: HHS Rejects Sole Source Award For Utah Study; Reagan Proclaims April Cancer Control Month

April 3, 1981

In Brief: Ways & Means Shakeup Means More Liberal Health Insurance Bill; OMB’s Nutty Rational For Cuts

December 20, 1974

No Cancer Letter For Next Two Weeks

August 19, 1994

New Organ Systems Concept Flow Discussed

October 18, 1985

Upton Wraps Up Reorganization – DCCR Revamped, No Prevention Division

October 12, 1979

In Brief: James Carr Replaces Murphy As Interim Director of Organ Systems Coordinating Center In N.Y.

August 16, 1985